Focus: Navamedic is a Norwegian public biotech company founded in 2006 specializing in small-molecule therapeutics for dermatology, metabolic diseases, and women's health across multiple therapeutic areas including cardiology and urology. The company operates as a focused mid-cap biotech with a concentrated portfolio approach.
Profile data last refreshed 19h ago · AI intelligence enriched 3w ago
No open roles listed right now. Follow Navamedic to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Navamedic's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Navamedic
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo